Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Costa Bachas

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Hemasphere|June 8, 2026
Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studiesCoen R Veenstra, Lok Lam Ngai, Patrycja Gradowska, et al.
Leukemia|September 3, 2025
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trialTim R Mocking, Lukas H Haaksma, Tom Reuvekamp, et al.
Haematologica|April 30, 2025
Different features of acute myeloid leukemia stem cell quantification in intensively treated patientsLok Lam Ngai, Tom Reuvekamp, Diana Hanekamp, et al.
Blood|March 10, 2023
Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trialLok Lam Ngai, Diana Hanekamp, Fleur Janssen, et al.
Blood|November 1, 2021
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Sylvie D Freeman, Gert J Ossenkoppele, et al.
Blood|December 15, 2025
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working PartyJacqueline Cloos, Peter J M Valk, Christian Thiede, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Hemasphere|June 8, 2026
Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studiesCoen R Veenstra, Lok Lam Ngai, Patrycja Gradowska, et al.
Leukemia|September 3, 2025
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trialTim R Mocking, Lukas H Haaksma, Tom Reuvekamp, et al.
Haematologica|April 30, 2025
Different features of acute myeloid leukemia stem cell quantification in intensively treated patientsLok Lam Ngai, Tom Reuvekamp, Diana Hanekamp, et al.
Blood|March 10, 2023
Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trialLok Lam Ngai, Diana Hanekamp, Fleur Janssen, et al.
Blood|November 1, 2021
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Sylvie D Freeman, Gert J Ossenkoppele, et al.
Blood|December 15, 2025
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working PartyJacqueline Cloos, Peter J M Valk, Christian Thiede, et al.
Pageof 4